Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU-045 vs Xeomin for Moderate to Severe Glabellar Lines
NCT05298449Phase 2Completed
- Sponsor
- Huons
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of HU-045 in glabellar lines, sponsored by Huons. Started Mar 2022; status: completed.
02
Drugs
HU-045
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05298449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298449.